Voyager Therapeutics, Inc.
VYGR · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $80,001 | $250,008 | $40,907 | $37,415 |
| % Growth | -68% | 511.2% | 9.3% | – |
| Cost of Goods Sold | $0 | $92,172 | $55,764 | $73,787 |
| Gross Profit | $80,001 | $157,836 | -$14,857 | -$36,372 |
| % Margin | 100% | 63.1% | -36.3% | -97.2% |
| R&D Expenses | $127,368 | $92,172 | $60,764 | $73,787 |
| G&A Expenses | $35,920 | $35,822 | $30,980 | $37,246 |
| SG&A Expenses | $35,920 | $35,822 | $30,980 | $37,246 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$92,172 | -$55,764 | -$73,787 |
| Operating Expenses | $163,288 | $35,822 | $35,980 | $37,246 |
| Operating Income | -$83,287 | $122,014 | -$50,837 | -$73,618 |
| % Margin | -104.1% | 48.8% | -124.3% | -196.8% |
| Other Income/Exp. Net | $18,950 | $11,724 | $4,445 | $2,421 |
| Pre-Tax Income | -$64,337 | $133,738 | -$46,392 | -$71,197 |
| Tax Expense | $665 | $1,408 | $16 | $0 |
| Net Income | -$65,002 | $132,330 | -$46,408 | -$71,197 |
| % Margin | -81.3% | 52.9% | -113.4% | -190.3% |
| EPS | -1.13 | 3.08 | -1.21 | -1.75 |
| % Growth | -136.7% | 354.5% | 30.9% | – |
| EPS Diluted | -1.13 | 2.97 | -1.21 | -1.75 |
| Weighted Avg Shares Out | 57,668 | 43,021 | 38,357 | 37,669 |
| Weighted Avg Shares Out Dil | 57,668 | 44,569 | 38,357 | 37,669 |
| Supplemental Information | – | – | – | – |
| Interest Income | $18,328 | $11,721 | $1,792 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $4,731 | $4,441 | $6,191 | $5,165 |
| EBITDA | -$78,556 | $126,455 | -$39,646 | -$68,453 |
| % Margin | -98.2% | 50.6% | -96.9% | -183% |